Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) was the recipient of a large decrease in short interest in the month of April. As of April 30th, there was short interest totaling 17,090 shares, a decrease of 58.2% from the April 15th total of 40,924 shares. Based on an average daily volume of 38,481 shares, the short-interest ratio is currently 0.4 days. Currently, 0.9% of the company’s stock are short sold.

Biodexa Pharmaceuticals Trading Down 2.9%

Shares of NASDAQ:BDRX opened at $3.30 on Friday. Biodexa Pharmaceuticals has a one year low of $2.86 and a one year high of $96.50. The business’s 50-day simple moving average is $3.75 and its 200 day simple moving average is $12.13.

Biodexa Pharmaceuticals (NASDAQ:BDRX) last announced its earnings results on Friday, March 27th. The company reported $3.52 EPS for the quarter, beating the consensus estimate of ($0.01) by $3.53.

Institutional Trading of Biodexa Pharmaceuticals

An institutional investor recently bought a new position in Biodexa Pharmaceuticals stock. Armistice Capital LLC bought a new stake in shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 100,000 shares of the company’s stock, valued at approximately $227,000. Armistice Capital LLC owned approximately 14.71% of Biodexa Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 17.51% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on BDRX. Weiss Ratings raised shares of Biodexa Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday. Wall Street Zen downgraded Biodexa Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, March 30th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.